二肽基肽酶4抑制剂对2型糖尿病患者骨代谢影响的研究进展  

Effect of dipeptidyl peptidase 4 inhibitors on bone metabolism in patients with type 2 diabetes mellitus

作　　者：汝子萱 丛丽[1] RU Zhuan;CONG Li(Department of Endocrinology and Metabolism,The Second Affiliated Hospital,Harbin Medical University,Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属第二医院内分泌代谢病科

出　　处：《中国糖尿病杂志》2019年第7期554-556,共3页Chinese Journal of Diabetes

基　　金：哈尔滨市青年后备人才基金资助项目(2017RAQXJ165)

摘　　要：糖尿病患者发生骨质疏松(OP)的概率高于正常人。二肽基肽酶4(DPP-4)抑制剂是一种相对新型的口服降糖药,广泛应用于T2DM的临床治疗。DPP-4抑制剂可能具有独立于降糖效果以外的骨代谢保护作用,与改变维生素D水平、抑制p38 MAPK-mi/Mitf磷酸化、抑制脂肪组织分化等多种途径有关。本文对DPP-4抑制剂影响T2DM患者骨代谢的研究进展进行综述,为临床治疗提供理论依据。It is well-known that diabetes coincides with an increased risk of osteoporosis(OP). Dipeptidyl peptidase 4(DPP-4)inhibitors are newly developed oral glucose-control medications,which have been widely used in treatment for type 2 diabetes mellitus(T2DM). DPP-4 inhibitors may have protective effect on bone metabolism. This effect is associated with increasing Vitamin D levels,inhibiting p38 MAPK-mi/Mitf phosphorylation,targeting the adipocytic lineage and other pathways. This article reviews the research progress of DPP-4 inhibitors on bone metabolism in patients with T2DM,and provides theoretical basis for clinical practice.

关 键 词：二肽基肽酶4抑制剂 糖尿病 2型 骨代谢 

分 类 号：R587.2[医药卫生—内分泌] R580[医药卫生—内科学]